Clostridium difficile infection: Prevention, treatment, and surgical management

Surgical Clinics of North America

Volumn 94, Issue 6, 2014, Pages 1335-1349

  Luciano, Jason A ^a   Zuckerbraun, Brian S ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Colectomy; Fecal microbiota therapy; Ileostomy; Vancomycin

Indexed keywords

FIDAXOMICIN; IMMUNOLOGIC AGENT; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE DISEASE; ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG INDUSTRY; FECES MICROFLORA; GOLD STANDARD; HUMAN; ILEOSTOMY; MORTALITY; NUCLEIC ACID AMPLIFICATION; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SIGMOIDOSCOPY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ISOLATION AND PURIFICATION; MULTIMODALITY CANCER THERAPY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COLECTOMY; COMBINED MODALITY THERAPY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; ILEOSTOMY; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84923818545     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.08.006     Document Type: Review

References (90)

1. Tedesco F.J., Barton R.W., Alpers D.H. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974, 81(4):429-433.
2. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. NEngl J Med 1978, 298(10):531-534.
3. Bartlett J.G., Moon N., Chang T.W., et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978, 75(5):778-782.
4. Walker K.J., Gilliland S.S., Vance-Bryan K., et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. JAm Geriatr Soc 1993, 41(9):940-946.
5. Surawicz C.M., Brandt L.J., Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013, 108(4):478-498.
6. Choi H.K., Kim K.H., Lee S.H., et al. Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization. JKorean Med Sci 2011, 26(7):859-864.
7. Garey K.W., Sethi S., Yadav Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. JHosp Infect 2008, 70(4):298-304.
8. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
9. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. NEngl J Med 2008, 359(18):1932-1940.
10. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008, 14(6):929-931.
11. Jarvis W.R., Schlosser J., Jarvis A.A., et al. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009, 37(4):263-270.
12. Vonberg R.P., Reichardt C., Behnke M., et al. Cost of nosocomial Clostridium difficile-associated diarrhoea. JHosp Infect 2008, 70:15-20.
13. Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012, 55(Suppl 2):S88-S92.
14. O'Brien J.A., Lahue B.J., Caro J.J., et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007, 28(11):1219-1227.
15. Redelings M.D., Sorvillo F., Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007, 13(9):1417-1419.
16. Khanna S., Pardi D.S., Aronson S.L., et al. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther 2012, 35(5):613-618.
17. Ozaki E., Kato H., Kita H., et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. JMed Microbiol 2004, 53(Pt 2):167-172.
18. Matsuki S., Ozaki E., Shozu M., et al. Colonization by Clostridium difficile of neonates in a hospital, and infants and children in three day-care facilities of Kanazawa, Japan. Int Microbiol 2005, 8(1):43-48.
19. Walker A.S., Eyre D.W., Wyllie D.H., et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med 2012, 9(2):e1001172.
20. Fekety R., Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993, 269(1):71-75.
21. Clabots C.R., Johnson S., Olson M.M., et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. JInfect Dis 1992, 166(3):561-567.
22. Samore M.H., DeGirolami P.C., Tlucko A., et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994, 18(2):181-187.
23. Kundrapu S., Sunkesula V.C., Jury L.A., et al. Utility of perirectal swab specimens for diagnosis of Clostridium difficile infection. Clin Infect Dis 2012, 55(11):1527-1530.
24. Zilberberg M.D., Shorr A.F., Micek S.T., et al. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med 2009, 37(9):2583-2589.
25. Welfare M.R., Lalayiannis L.C., Martin K.E., et al. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. JHosp Infect 2011, 79(4):359-363.
26. Hall I.C., O'Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935, 49(2):390-402.
27. Bacci S., Molbak K., Kjeldsen M.K., et al. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011, 17(6):976-982.
28. Barbut F., Decre D., Lalande V., et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. JMed Microbiol 2005, 54(Pt 2):181-185.
29. Stewart D.B., Berg A., Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. JGastrointest Surg 2013, 17(1):118-124.
30. Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377(9759):63-73.
31. Smits T.H., Rezzonico F., Lopez M.M., et al. Phylogenetic position and virulence apparatus of the pear flower necrosis pathogen Erwinia piriflorinigrans CFBP 5888(T) as assessed by comparative genomics. Syst Appl Microbiol 2013, 36(7):449-456.
32. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366(9491):1079-1084.
33. Vedantam G., Clark A., Chu M., et al. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 2012, 3(2):121-134.
34. Lanis J.M., Barua S., Ballard J.D. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 2010, 6(8):e1001061.
35. Lanis J.M., Hightower L.D., Shen A., et al. TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol Microbiol 2012, 84(1):66-76.
36. Loo V.G., Poirier L., Miller M.A., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEngl J Med 2005, 353(23):2442-2449.
37. Planche T., Aghaizu A., Holliman R., et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008, 8(12):777-784.
38. Fleshner M. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome. Brain Behav Immun 2013, 27(1):1-7.
39. Barbut F., Delmee M., Brazier J.S., et al. AEuropean survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003, 9(10):989-996.
40. Stanley J.D., Burns R.P. Clostridium difficile and the surgeon. Am Surg 2010, 76(3):235-244.
41. Cheng A.C., Ferguson J.K., Richards M.J., et al. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust 2011, 194(7):353-358.
42. Crobach M.J., Dekkers O.M., Wilcox M.H., et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009, 15(12):1053-1066.
43. Luo R.F., Banaei N. Is repeat PCR needed for diagnosis of Clostridium difficile infection?. JClin Microbiol 2010, 48(10):3738-3741.
44. Debast S.B., van Kregten E., Oskam K.M., et al. Effect on diagnostic yield of repeated stool testing during outbreaks of Clostridium difficile-associated disease. Clin Microbiol Infect 2008, 14(6):622-624.
45. Deshpande A., Pasupuleti V., Pant C., et al. Potential value of repeat stool testing for Clostridium difficile stool toxin using enzyme immunoassay?. Curr Med Res Opin 2010, 26(11):2635-2641.
46. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31(4):1012-1017.
47. Gujja D., Friedenberg F.K. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009, 29(6):635-642.
48. Fujitani S., George W.L., Murthy A.R. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011, 32(3):220-228.
49. Keighley M.R., Burdon D.W., Arabi Y., et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 1978, 2(6153):1667-1669.
50. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. Acomparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45(3):302-307.
51. Al-Nassir W.N., Sethi A.K., Nerandzic M.M., et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008, 47(1):56-62.
52. Apisarnthanarak A., Razavi B., Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002, 35(6):690-696.
53. Crook D.W., Walker A.S., Kean Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012, 55(Suppl 2):S93-S103.
54. Louie T.J., Cannon K., Byrne B., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012, 55(Suppl 2):S132-S142.
55. Cornely O.A., Miller M.A., Louie T.J., et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012, 55(Suppl 2):S154-S161.
56. Sailhamer E.A., Carson K., Chang Y., et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009, 144(5):433-439.
57. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235(3):363-372.
58. Byrn J.C., Maun D.C., Gingold D.S., et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008, 143(2):150-154.
59. Hall J.F., Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg 2008, 196(3):384-388.
60. Dudukgian H., Sie E., Gonzalez-Ruiz C., et al. C. difficile colitis-predictors of fatal outcome. JGastrointest Surg 2010, 14(2):315-322.
61. Synnott K., Mealy K., Merry C., et al. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 1998, 85(2):229-231.
62. Pepin J., Vo T.T., Boutros M., et al. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum 2009, 52(3):400-405.
63. Ali S.O., Welch J.P., Dring R.J. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 2008, 74(1):20-26.
64. Butala P., Divino C.M. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg 2010, 200(1):131-135.
65. Markelov A., Livert D., Kohli H. Predictors of fatal outcome after colectomy for fulminant Clostridium difficile colitis: a 10-year experience. Am Surg 2011, 77(8):977-980.
66. Perera A.D., Akbari R.P., Cowher M.S., et al. Colectomy for fulminant Clostridium difficile colitis: predictors of mortality. Am Surg 2010, 76(4):418-421.
67. Medich D.S., Lee K.K., Simmons R.L., et al. Laparotomy for fulminant pseudomembranous colitis. Arch Surg 1992, 127(7):847-852.
68. Neal M.D., Alverdy J.C., Hall D.E., et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011, 254(3):423-427.
69. Petrella L.A., Sambol S.P., Cheknis A., et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012, 55(3):351-357.
70. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41(9):1254-1260.
71. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97(7):1769-1775.
72. Chang J.Y., Antonopoulos D.A., Kalra A., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. JInfect Dis 2008, 197(3):435-438.
73. Bakken J.S., Borody T., Brandt L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9(12):1044-1049.
74. Eiseman B., Silen W., Bascom G.S., et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44(5):854-859.
75. Khoruts A., Dicksved J., Jansson J.K., et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. JClin Gastroenterol 2010, 44(5):354-360.
76. Kassam Z., Lee C.H., Yuan Y., et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013, 108(4):500-508.
77. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2011, 9(2):88-96.
78. Bakken J.S. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009, 15(6):285-289.
79. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53(10):994-1002.
80. Guo B., Harstall C., Louie T., et al. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012, 35(8):865-875.
81. van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEngl J Med 2013, 368(5):407-415.
82. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. NEngl J Med 2010, 362(3):197-205.
83. Gouliouris T., Brown N.M., Aliyu S.H. Prevention and treatment of Clostridium difficile infection. Clin Med 2011, 11(1):75-79.
84. Jones A.M., Kuijper E.J., Wilcox M.H. Clostridium difficile: a European perspective. JInfect 2013, 66(2):115-128.
85. Gao X.W., Mubasher M., Fang C.Y., et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010, 105(7):1636-1641.
86. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007, 335(7610):80.
87. Johnson S., Homann S.R., Bettin K.M., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992, 117(4):297-302.
88. Foglia G., Shah S., Luxemburger C., et al. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012, 30(29):4307-4309.
89. Kink J.A., Williams J.A. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998, 66(5):2018-2025.
90. Babcock G.J., Broering T.J., Hernandez H.J., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006, 74(11):6339-6347.